RE:Validation Results at EMMDQuestion is.. how long does eventually take? In the case of urokinase a photo finish has turned into indefinite. In the case of VTM it appears there was no new order from Ontario and hence Q4 VTM revenue will probably be somewhere from 100 to 300K. This is notable because VTM represented greater than 30% of revenue in Q's 1, 2 &3. So how will MBX replace this in Q4 and Q1 23?
The QAP deal was anounced near mid August so probably doubtful that could fill the VTM gap with just 2 weeks of sales... but who knows?
Seems MBX has fallen out of favor long before the market downturn and it investors are now just waiting for the next shoe to drop? If Q4 revenue does come up short it will also coinside with a huge expense line since headcount recently surpassed 130. I believe HC was well under 100 12 months ago so any hickup in the revenue line will hit earnings very hard.
I'm not saying this is the case because I have no inside information but if it is I really hope management will get out in front of this with news and investor out reach.
Also, all this makes me wonder if what the above portends is why the CEO, CFO and BOD been selling selling and selling? If they thought the share price was going to rise on continued earnings one would think they would at least continue to hold.
I do understand the big options purchases need to be paid for and management has skin in the game but 23 cent options are a far cry from what investors have paid during the last capital raise at 60c some 16 months ago and other market investors buying all the way up to 80c. Management and BOD are not suffering with the current share price nor will they even if the price falls further, but regular shareholders are suffering now and could suffer a lot more. I wish managemnt would show a little more empathy for its shareholders!
Still there have been a lot of positive developments and it seems MBX has a lot of potential however with all the added fixed costs MBX has become a far riskier investment and that seems to be bourne out in the waning share price and very low trading volumes and investor interest.
I view the NCIB as a bit of a red herring and I don't expect any meaningful buying. After all MBX should be preserving they're cash and besides the max daily purchases are just 11k shares which is nowhere near enough to defend the share price if investors decide to bail.
The ball is in managements court and its all about executing on the business and not useless ads on stockhouse which really do nothing for customer or shareholder awareness much less the stock price.
All that said GO MBX GO. Hopefully we hear of additional QAP deals very soon.
D
PS. Someone suggested targetting funds towards urokinase and I support that as its a great asset and moving it along would make it so much easier to sign a partner.